Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.
Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.
Fusion Antibodies signed an agreement with Analytics Engines to bring machine learning and AI to its humanization platform in an aim to bolster product quality and manufacturability.
The life sciences company, ForteBio, has launched its Dip and Read Protein G biosensor, designed for the fast-track analysis of specific biomolecular interactions of various types of the antibody molecule, mammalian immunoglobulin.
